Skip to main content

Advertisement

Table 1 Patient characteristics and disease parameters

From: Evaluation of treatments for sacroiliitis in spondyloarthropathy using the Spondyloarthritis Research Consortium Canada scoring system

  All Anti-TNF alone Anti-TNF + DMARDs DMARDs alone
Age (years) 21 (15–36) 23 (15–29) 27 (18–32) 28 (22–36)
Gender (male/female) 12/44 3/15 6/15 3/14
Disease duration 2 (0.17–10) 0.67 (0.17–3) 2 (0.75–6) 7.5 (3.5–10)
HLA-B27-positive 91.1 % (51/56) 88.9 % (16/18) 90.5 % (19/21) 94.1 % (16/17)
Baseline
 SPARCC 32.45 ± 18.71 27.76 ± 18.38 39.53 ± 19.21 28.67 ± 15.51
 ASDAS 2.84 ± 1.26 2.56 ± 1.24 3.58 ± 1.05 2.21 ± 1.03
 ESRa 27.10 ± 32.39 27.94 ± 33.24 38.49 ± 38.50 12.14 ± 8.43
 CRPa 17.50 ± 23.07 16.29 ± 23.05 26.29 ± 28.02 7.919 ± 5.60
  1. aNot normally distributed, compared by paired rank test
  2. ASDAS Ankylosing Spondylitis Disease Activity Indices, CRP C-reactive protein, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate, SPARCC Spondyloarthritis Research Consortium Canada, TNF tumor necrosis factor